Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021
News provided by
Share this article
Share this article
RED BANK, N.J., April 29, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its first quarter 2021 financial results on Thursday, May 6, 2021, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.
To access the call, please dial 1-877-870-4263 (domestic) or 1-412-317-0790 (international) ten minutes prior to the start time and ask to be connected to the Provention Bio Call. An audio webcast will also be available on the Events and Webcasts page of the Investors section of the Company s website, www.proventionbio.com. An archived webcast will be available on the Company s website
Share this article
Share this article
RED BANK, N.J., April 8, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the Company received a notification on April 2, 2021 from the U.S. Food and Drug Administration (FDA), stating that, as part of its ongoing review of the Company s Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes, the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time. The FDA stated in the correspondence that the notification does not reflect a final decision on the information under review.
Provention Bio to Present at Two Upcoming Virtual Investor Conferences
News provided by
Share this article
Share this article
RED BANK, N.J., March 4, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in two upcoming virtual investor conferences in March.
H.C. Wainwright Global Life Sciences Conference
Andrew Drechsler, Provention Bio s Chief Financial Officer will provide a corporate update at the H.C. Wainwright Global Life Sciences Conference. The webcast will be available beginning Tuesday, March 9, 2021, at 7:00 am E.T and can be accessed by visiting the Events and Webcasts section of the Company s website: http://investors.proventionbio.com/events.
Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
-U.S. Food and Drug Administration (FDA) filing of a Biologics License Application (BLA) and Priority Review for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals; PDUFA goal date of July 2, 2021-
News provided by
Share this article
Share this article
RED BANK, N.J., Feb. 25, 2021 /PRNewswire/ Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended December 31, 2020. 2020 was a pivotal year for Provention Bio and the type 1 diabetes (T1D) landscape, stated Ashleigh Palmer, CEO of Provention Bio. The FDA s filing of our BLA for teplizumab represents a momentous achievement for Provention Bio in our mission to potentially deliver the first disease-modifying T1D therapy, which may cat